Drugs / PolyTregs
PolyTregs
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03444064 | Feb 2018 → Aug 2024 | type 1 diabetes mellitus | University of Alberta | Completed | No outcome recorded |
| Phase 1 | NCT03239470 | Oct 2017 → Dec 2020 | pemphigus foliaceus, pemphigus vulgaris | National Institute of Allergy and Infectious Diseases (NIAID) | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1 | NCT02772679 | Aug 2016 → Aug 2021 | type 1 diabetes mellitus | Jeffrey Bluestone | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PolyTregs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03239470 ↗ |
| Known as | polyclonal regulatory T cells | “The investigators hypothesize that ex vivo expanded human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells (Polyclonal Tregs) plus Interleukin-2 (IL-2) administered...” NCT02772679 ↗ |
| Known as | Polyclonal Tregs | “The investigators hypothesize that ex vivo expanded human autologous CD4+CD127lo/-CD25+ polyclonal regulatory T cells (Polyclonal Tregs) plus Interleukin-2 (IL-2) administered...” NCT02772679 ↗ |
| Modality | Cell therapy | “Autologous Polyclonal Regulatory T Cell Therapy” NCT03239470 ↗ |
| Route | Other | “PolyTregs will be infused into the patient in a single infusion.” NCT02772679 ↗ |